New Insights Into Peptide Cannabinoids: Structure, Biosynthesis and Signaling

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• The classical endocannabinoid system (ECS) comprises endogenous lipids like anandamide (AEA) and 2-arachidonoylglycerol (2-AG), their synthesis/degradation enzymes, and cannabinoid receptors CB1 and CB2.
• Endocannabinoids also interact with non-classical receptors, and other lipid classes are considered endocannabinoids.
• The hemopressin peptide family, derived from hemoglobin, represents a newly identified class of cannabinoids.

Purpose of the Study:

• To review emerging evidence on lipid endocannabinoids and cannabinoid receptors.
• To discuss the pharmacological effects and biosynthesis of peptide cannabinoids.
• To explore novel insights into the activation and modulation of cannabinoid receptors by these peptides.

Main Methods:

• Literature review of recent studies on endocannabinoids and cannabinoid receptors.
• Analysis of research on peptide cannabinoid biosynthesis and function.
• Examination of data on non-classical activation of cannabinoid receptors.

Main Results:

• Hemopressin peptides, derived from hemoglobin, function as novel cannabinoids.
• These peptides are expressed in the central nervous system and peripheral tissues.
• Evidence suggests hemopressin peptides play a physiological role through receptor interactions.

Conclusions:

• Peptide cannabinoids represent a significant expansion of the known endocannabinoid system.
• Their non-classical activation of cannabinoid receptors opens new avenues for research.
• These findings highlight the potential of peptide cannabinoids as future therapeutic agents.